226 related articles for article (PubMed ID: 30008256)
21. Reduced FHIT expression is associated with tumor progression in sporadic colon adenocarcinoma.
Kapitanović S; Čačev T; Lončar B; Catela Ivković T; Križanac Š; Pavelić K
Exp Mol Pathol; 2014 Feb; 96(1):92-7. PubMed ID: 24370550
[TBL] [Abstract][Full Text] [Related]
22. Association of allelic loss at the FHIT locus and p53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs).
Garinis GA; Gorgoulis VG; Mariatos G; Zacharatos P; Kotsinas A; Liloglou T; Foukas P; Kanavaros P; Kastrinakis NG; Vassilakopoulos T; Vogiatzi T; Field JK; Kittas C
J Pathol; 2001 Jan; 193(1):55-65. PubMed ID: 11169516
[TBL] [Abstract][Full Text] [Related]
23. Enduring response to everolimus as third-line therapy in a patient with advanced renal cell carcinoma, including small-bowel metastases: loss of FHIT but normal VHL gene status.
Broom RJ; Caldwell I; Hanning F; Fong P; Deva S; Oei P
Clin Genitourin Cancer; 2012 Sep; 10(3):202-6. PubMed ID: 22440786
[No Abstract] [Full Text] [Related]
24. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
[TBL] [Abstract][Full Text] [Related]
25. Analysis of FHIT allelic imbalance/loss of heterozygosity and FHIT expression in cutaneous squamous cell carcinomas.
Gray SE; Kay E; Leader M; Mabruk M
J Cutan Pathol; 2008 Sep; 35(9):816-25. PubMed ID: 18494825
[TBL] [Abstract][Full Text] [Related]
26. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
[TBL] [Abstract][Full Text] [Related]
27. Alterations of the FHIT gene in breast cancer: association with tumor progression and patient survival.
Ingvarsson S; Sigbjornsdottir BI; Huiping C; Jonasson JG; Agnarsson BA
Cancer Detect Prev; 2001; 25(3):292-8. PubMed ID: 11425271
[TBL] [Abstract][Full Text] [Related]
28. [Loss of heterozygosity in the 9p21 region as an inactivation mechanism of the p16 suppressor gene].
Maestro de las Casas ML; Sanz-Casla MT; del Barco V; Moreno J; Zanna I; Redondo E; Fernández C; Izquierdo L; Resel Estévez L
Arch Esp Urol; 2000 Sep; 53(7):603-9. PubMed ID: 11037653
[TBL] [Abstract][Full Text] [Related]
29. Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features.
Geradts J; Fong KM; Zimmerman PV; Minna JD
Br J Cancer; 2000 Mar; 82(6):1191-7. PubMed ID: 10735505
[TBL] [Abstract][Full Text] [Related]
30. [The loss of heterozygosity on the short arm of chromosome 3 in renal carcinoma].
Maestro de las Casas ML; del Barco Barriuso V; Moreno Sierra J; Izquierdo López L; Sanz Casla MT; Zanna I; Redondo González E; Chicharro Almarza J; Fernández Pérez C; Resel Estévez L
Arch Esp Urol; 1999; 52(1):3-9. PubMed ID: 10101881
[TBL] [Abstract][Full Text] [Related]
31. Aberration of FHIT gene is associated with increased tumor proliferation and decreased apoptosis-clinical evidence in lung and head and neck carcinomas.
Pavelić K; Krizanac S; Cacev T; Hadzija MP; Radosević S; Crnić I; Levanat S; Kapitanović S
Mol Med; 2001 Jul; 7(7):442-53. PubMed ID: 11683369
[TBL] [Abstract][Full Text] [Related]
32. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer.
Burke L; Khan MA; Freedman AN; Gemma A; Rusin M; Guinee DG; Bennett WP; Caporaso NE; Fleming MV; Travis WD; Colby TV; Trastek V; Pairolero PC; Tazelaar HD; Midthun DE; Liotta LA; Harris CC
Cancer Res; 1998 Jun; 58(12):2533-6. PubMed ID: 9635574
[TBL] [Abstract][Full Text] [Related]
33. Reduced Fhit protein expression in human malignant mesothelioma.
Pylkkänen L; Wolff H; Stjernvall T; Knuuttila A; Anttila S; Husgafvel-Pursiainen K
Virchows Arch; 2004 Jan; 444(1):43-8. PubMed ID: 14569398
[TBL] [Abstract][Full Text] [Related]
34. Alterations of FHIT and P53 genes in keratocystic odontogenic tumor, dentigerous and radicular cyst.
Malcić A; Jukić S; Anić I; Pavelić B; Kapitanović S; Kruslin B; Pavelić K
J Oral Pathol Med; 2008 May; 37(5):294-301. PubMed ID: 18221322
[TBL] [Abstract][Full Text] [Related]
35. Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis.
Velickovic M; Delahunt B; McIver B; Grebe SK
Mod Pathol; 2002 May; 15(5):479-85. PubMed ID: 12011252
[TBL] [Abstract][Full Text] [Related]
36. Aberrations in the fragile histidine triad(FHIT) gene may be involved in lung carcinogenesis in patients with chronic pulmonary tuberculosis.
Song L; Yan W; Deng M; Song S; Zhang J; Zhao T
Tumour Biol; 2004; 25(5-6):270-5. PubMed ID: 15627891
[TBL] [Abstract][Full Text] [Related]
37. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.
Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
Cancer Res; 2003 Jul; 63(13):3724-8. PubMed ID: 12839965
[TBL] [Abstract][Full Text] [Related]
38. Loss of heterozygosity on the short arm of chromosome 3 in renal cancer.
Maestro ML; del Barco V; Sanz-Casla MT; Moreno J; Adrover E; Izquierdo L; Zanna I; Fernández C; Redondo E; Blanco J; Resel L
Oncology; 2000 Aug; 59(2):126-30. PubMed ID: 10971171
[TBL] [Abstract][Full Text] [Related]
39. Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer.
Fullwood P; Marchini S; Rader JS; Martinez A; Macartney D; Broggini M; Morelli C; Barbanti-Brodano G; Maher ER; Latif F
Cancer Res; 1999 Sep; 59(18):4662-7. PubMed ID: 10493522
[TBL] [Abstract][Full Text] [Related]
40. Fragile histidine triad (FHIT) gene is overexpressed in colorectal cancer.
Wierzbicki PM; Adrych K; Kartanowicz D; Dobrowolski S; Stanislawowski M; Chybicki J; Godlewski J; Korybalski B; Smoczynski M; Kmiec Z
J Physiol Pharmacol; 2009 Oct; 60 Suppl 4():63-70. PubMed ID: 20083853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
